EDTUTC-4 New YorkLog in Sign up

ROIV
Roivant Sciences Ltd. Common Shares
stockNASDAQ

Market OpenOct 29, 2026 12:00:44 PM EDT

37.82USD+1.913%(+0.71)1,246,982

Pre-marketOct 29, 2026 9:26:30 AM EDT

37.29USD+0.485%(+0.18)

37.80Bid37.82Ask0.02Spread

ROIV News

Day breaks

09:00 AM EDTRoivant Social Ventures Announced Support of No Patient Left Behind with Six-Figure Organizational Legacy Gift ·

GlobeNewswire Inc.

03:04 PM EDTRoivant Sciences Ltd. (ROIV) Discusses Phase 3 Results for Brepocitinib in Non-Infectious Uveitis Transcript ·

Seeking Alpha

10:13 AM EDTWhy is Roivant Sciences stock rallying today? ·

Investing.com

09:23 AM EDTRoivant to seek label expansion for Lisraya in uveitis after late-stage trial win ·

Seeking Alpha

08:39 AM EDTRoivant Sciences stock surges on positive uveitis trial data ·

Investing.com

07:00 AM EDTImmunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026 ·

GlobeNewswire Inc.

07:00 AM EDTRoivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU) ·

GlobeNewswire Inc.

10:56 AM EDTRoivant Sciences added to Citi's 90-day catalyst watch ·

Seeking Alpha

12:51 PM EDTArbutus gains on plans to buy back 46M shares in tender offer ·

Seeking Alpha

07:50 AM EDTCantor Fitzgerald reiterates Roivant Sciences stock rating ·

Investing.com

07:27 AM EDTRoivant slips as Immunovant faces trial setback for cutaneous lupus therapy ·

Seeking Alpha

02:29 PM EDTRoivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2026 Transcript ·

Seeking Alpha

06:27 AM EDTRoivant (ROIV): $9 Billion Sales Potential Faces a Commercialization Test ·

Insider Monkey

02:57 PM EDTFDA, Duke-Margolis workshop to examine evidence standards for rare diseases ·

Seeking Alpha

08:48 AM EDTJPMorgan reiterates Roivant Sciences stock rating on survey data ·

Investing.com

04:52 PM EDTStifel initiates Roivant Sciences stock with buy rating, $51 target ·

Investing.com

07:15 AM EDTCompany News for Sep 9, 2026 ·

Zacks Investment Research

08:00 AM EDTDr. Gillian Cannon Joins Lindus Therapeutics’ Board as a Non-Executive Director ·

GlobeNewswire Inc.